Professor | Guifeng Wang | Asia Growth Partners

Name	Guifeng Wang
Contact Information	GFWang@simm.ac.cn
Language ability	Chinese, English
Province	Shanghai

Name

Guifeng Wang

Contact Information

GFWang@simm.ac.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Medical School
Academic Background & Achievements	2003-09--2006-07 Ph.D.: Shanghai Institute of Materia Medica 2000-09--2003-07 Master's Degree: Jilin University 1996-09--2000-07 Bachelor's Degree: Jilin University
Work Experience	2023-10~Present - Shanghai Institute of Materia Medica - Researcher 2008-10~2023-09 - Shanghai Institute of Materia Medica - Associate Researcher 2006-07~2008-09 - Shanghai Institute of Materia Medica - Assistant Researcher 2024-01-15~Present - Nanjing University of Chinese Medicine - Graduate Advisor

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Medical School

Academic Background & Achievements

2003-09--2006-07 Ph.D.: Shanghai Institute of Materia Medica
2000-09--2003-07 Master's Degree: Jilin University
1996-09--2000-07 Bachelor's Degree: Jilin University

Work Experience

2023-10~Present - Shanghai Institute of Materia Medica - Researcher
2008-10~2023-09 - Shanghai Institute of Materia Medica - Associate Researcher
2006-07~2008-09 - Shanghai Institute of Materia Medica - Assistant Researcher
2024-01-15~Present - Nanjing University of Chinese Medicine - Graduate Advisor

Areas of Focus	Immunopharmacology Clinical Chinese Medicine
Publications	Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster, 3rd Author, 2023 ACE2-Targeting Antibody Suppresses SARS-CoV-2 Omicron and Delta Variants, Not mentioned, 2022 PD-L1/TIGIT bispecific antibody showed survival advantage in animal model, Not mentioned, 2022 Tyrphostin A9 protects axons in experimental autoimmune encephalomyelitis through activation of ERKs, Not mentioned, 2022 ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker, 4th Author, 2021 Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion, 3rd Author, 2014 Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus, 2nd Author, 2011 Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro, 1st Author, 2009 Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors, 3rd Author, 2008 Anti-Hepatitis B Virus Drugs in Clinical and Preclinical Development, 1st Author, 2008 Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus, 2nd Author, 2007 Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives, 2nd Author, 2006

Areas of Focus

Immunopharmacology
Clinical Chinese Medicine

Publications

Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster, 3rd Author, 2023
ACE2-Targeting Antibody Suppresses SARS-CoV-2 Omicron and Delta Variants, Not mentioned, 2022
PD-L1/TIGIT bispecific antibody showed survival advantage in animal model, Not mentioned, 2022
Tyrphostin A9 protects axons in experimental autoimmune encephalomyelitis through activation of ERKs, Not mentioned, 2022
ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker, 4th Author, 2021
Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion, 3rd Author, 2014
Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus, 2nd Author, 2011
Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro, 1st Author, 2009
Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors, 3rd Author, 2008
Anti-Hepatitis B Virus Drugs in Clinical and Preclinical Development, 1st Author, 2008
Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus, 2nd Author, 2007
Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives, 2nd Author, 2006

Immunopharmacology Clinical Chinese Medicine Sars-Cov-2 Antiviral Agents Hepatitis B Monoclonal Antibodies Autoimmune Diseases Inflammatory Bowel Disease Rheumatoid Arthritis Emerging Infectious Diseases

Jianping Zuo - University of Chinese Academy of Sciences

Fuping Zhang - University of Chinese Academy of Sciences

Chao Wu - Nanjing University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us